Metabolic Profiling Reveals PAFAH1B3 as a Critical Driver of Breast Cancer Pathogenicity

Melinda M. Mulvihill,1 Daniel I. Benjamin,1 Xiaodan Ji,2 Erwan Le Scolan,2 Sharon M. Louie,1 Alice Shieh,1 McKenna Green,1 Tara Narasimhalu,1 Patrick J. Morris,1 Kunxin Luo,2 and Daniel K. Nomura1,*

1Department of Nutritional Sciences and Toxicology, University of California, Berkeley, 127 Morgan Hall, Berkeley, CA 94720, USA
2Department of Molecular and Cell Biology, University of California, Berkeley, GL41 Koshland Hall, Berkeley, CA 94720, USA
*Correspondence: dnomura@berkeley.edu
http://dx.doi.org/10.1016/j.chembiol.2014.05.008

SUMMARY

Many studies have identified metabolic pathways that underlie cellular transformation, but the metabolic drivers of cancer progression remain less well understood. The Hippo transducer pathway has been shown to confer malignant traits on breast cancer cells. In this study, we used metabolic mapping platforms to identify biochemical drivers of cellular transformation and malignant progression driven through RAS and the Hippo pathway in breast cancer and identified platelet-activating factor acetylhydrolase 1B3 (PAFAH1B3) as a key metabolic driver of breast cancer pathogenicity that is upregulated in primary human breast tumors and correlated with poor prognosis. Metabolomic profiling suggests that PAFAH1B3 inactivation attenuates cancer pathogenicity through enhancing tumor-suppressing signaling lipids. Our studies provide a map of altered metabolism that underlies breast cancer progression and put forth PAFAH1B3 as a critical metabolic node in breast cancer.

INTRODUCTION

Cancer cells possess fundamentally dysregulated metabolism that underlies their pathogenic features (Benjamin et al., 2012; Vander Heiden et al., 2009). Targeting altered metabolism in cancer cells has historically served as a validated strategy for treating cancer patients. These therapies include chemotherapeutics such as 5-fluorouracil, methotrexate, and anastrozole that target certain aspects of cancer metabolism, fail to eradicate the most aggressive cancers (Chambers et al., 2002).

Studies over the past decade have uncovered a subpopulation of cancer cells termed cancer stem/precursor cells (CSCs) that, like embryonic stem cells, can undergo a process of epithelial-to-mesenchymal transition (EMT), which is associated with self-renewing and tumor-initiating capabilities, poor prognosis, and chemotherapy resistance within breast tumors (Polyak and Weinberg, 2009). Recent studies have identified TAZ, a transducer of the Hippo pathway, as a critical factor that is elevated in poorly differentiated human breast tumors, is correlated with poor prognosis, promotes EMT, is stabilized by EMT, and is required to sustain self-renewal and tumor-initiation capacities of breast CSCs (Cordenonsi et al., 2011; Hong and Guan, 2012). Identifying altered metabolic pathways that underlie both cellular transformation and malignant progression through TAZ may thus yield therapeutic strategies for combating malignant breast cancers.

WHEREAS targeting dysregulated metabolism is a promising therapeutic strategy for cancer treatment, nearly all research in cancer metabolism has focused on well-understood metabolic pathways in central carbon metabolism and has largely ignored the majority of cellular metabolic pathways, despite genetic or metabolic evidence of their involvement in cancer. This is in large part because of our incomplete understanding of metabolic networks in normal physiology, let alone in dysregulated or rewired biochemical networks in human cancer cells (Benjamin et al., 2012).

In this study, we used proteomic, functional proteomic, and metabolomic platforms to more broadly identify commonly altered metabolic pathways that underlie both mammary epithelial cell transformation by the oncogene HRAS as well as malignant progression, EMT, and cancer-stem-cell-like features through the constitutive activation of TAZ in the MCF10A non-transformed mammary epithelial cell line background. Through these profiling efforts, we have identified platelet-activating factor acetylhydrolase 1B3 (PAFAH1B3) as a critical enzyme in maintaining breast cancer cell aggressiveness and tumor growth through regulating tumor-suppressing lipids.

RESULTS AND DISCUSSION

Breast Cancer Progression Model

In this study, we used integrated metabolic mapping platforms to identify enzymes and metabolites that are dysregulated in a MCF10A breast cancer progression model, a series of isogenically derived human mammary cell lines consisting of non-transformed MCF10A cells, HRAS-transformed MCF10A-T1k cells...
A  

**shotgun proteomics**

<table>
<thead>
<tr>
<th>10A TAZ S89A</th>
<th>MII TAZ S89A</th>
<th>MIV</th>
<th>TCA cycle</th>
<th>amino acid metabolism</th>
<th>nucleic acid metabolism</th>
<th>lipid metabolism</th>
<th>collagen and extracellular matrix</th>
<th>higher expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENO1</td>
<td>GAPDH</td>
<td>PKM2</td>
<td>PGK1</td>
<td>LDHA</td>
<td>ALDOA</td>
<td>FASN</td>
<td>PYGB</td>
<td></td>
</tr>
</tbody>
</table>

B  

**activity-based protein profiling of serine hydrolases**

<table>
<thead>
<tr>
<th>10A TAZ S89A</th>
<th>MII TAZ S89A</th>
<th>MIV</th>
<th>DPP9</th>
<th>APEH</th>
<th>PREP</th>
<th>PAFAH1B2</th>
<th>PAFAH1B3</th>
<th>SIAE</th>
<th>FASN</th>
</tr>
</thead>
<tbody>
<tr>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
<td>spectral counts</td>
</tr>
</tbody>
</table>

C  

**metabolomics**

<table>
<thead>
<tr>
<th>10A TAZ S89A</th>
<th>MII TAZ S89A</th>
<th>MIV</th>
<th>TCA cycle</th>
<th>FFA, ACs, sphingolipids and neutral lipids</th>
<th>lipids</th>
<th>phospholipids</th>
<th>glycerol-3-phosphate</th>
<th>serine</th>
<th>glutathione</th>
</tr>
</thead>
<tbody>
<tr>
<td>C16:0/C18:1 PE</td>
<td>C16:0/C18:1 PS</td>
<td>C18:0 SM</td>
<td>PEP</td>
<td>AMP</td>
<td>UMP</td>
<td>UDP-glucuronic acid</td>
<td>N-acetyl neuraminic acid</td>
<td>proline</td>
<td>glutathione</td>
</tr>
</tbody>
</table>

(legend on next page)
(premalignant, also known as MII), and fully malignant MCF10A-CA1a (MIV) cells, derived in vivo from spontaneous progression of MII cells (Santner et al., 2001; Figure S1 available online). With in vivo orthotopic models, MII cells generate low-grade tumors in approximately 25% of xenografts, whereas the MIV lines form high-grade tumors, resembling grade III human breast tumors, at a much higher frequency. This well-characterized progression model displays many important features of breast cancer progression found in highly aggressive metaplastic and claudin-low breast tumor subtypes including EMT, expansion of CSC, metastasis, and an increased CSC population than MII cells, resembling the difference between grade III and grade I human breast tumors. By analyzing a large human patient data set, they identified TAZ as a key signature that is overrepresented in poorly differentiated high-grade tumors and correlates with increased CSCs, metastasis, and reduced survival. TAZ, a transducer of the Hippo-signaling pathway that mediates cell-cell contact and polarity signals to control cell proliferation and organ size (Chan et al., 2011), is also expressed at higher levels in MIV cells than MII cells and is required to sustain self-renewal and tumorigenesis capacities in breast CSCs. Consistent with previous reports, we show that expression of a constitutively active TAZ, TAZ S89A, in MCF10A or MII cells results in increased EMT, colony formation in soft agar, and cellular migration (Cordenonsi et al., 2011; Figure S1).

Identifying Dysregulated Metabolic Pathways Underlying Cellular Transformation and Malignant Progression

Our goal was to employ multiple metabolic mapping platforms to broadly identify dysregulated metabolic pathways that underlie cellular transformation and malignant progression using the aforementioned breast cancer model. We performed shotgun proteomic analysis, activity-based protein profiling (ABPP) using the serine hydrolase-directed activity-based probe, and targeted single reaction monitoring (SRM) liquid chromatography/mass spectrometry (LC/MS)-based metabolomic analyses to identify commonly altered changes in protein expression of metabolic enzymes, activities of serine hydrodases, and metabolite levels, respectively, that may underlie cellular transformation and TAZ-mediated malignant progression. Whereas shotgun proteomic profiling provides broad coverage of alterations in protein expression, ABPP uses active-site-directed chemical probes to identify dysregulated activities of large numbers of enzymes (Nomura et al., 2010a). We chose to profile the serine hydrolase superfamily for this study because this enzyme class is one of the largest metabolic enzyme classes in the human genome with a broad range of functions including esterase, lipase, hydrolase, deacetylase, thioesterase, protease, and peptidase activities, and many serine hydrolases have been shown to be important in cancer (Long and Cravatt, 2011). Through these profiling efforts, we identified several enzymes and lipids that were either specifically upregulated by constitutive activation of TAZ or commonly upregulated in 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells (Figures 1A–1C and S1; Table S1). The dysregulated enzymes identified through shotgun proteomics include glycolytic enzymes (enolase 1 [ENO1], glyceraldehyde-3-phosphate dehydrogenase [GAPDH], PKM2, phosphoglycerate kinase [PGK1], lactate dehydrogenase A [LDHA], and aldolase A [ALDOA]), the de novo lipogenesis enzyme FASN, and the glycogen-metabolizing enzyme glycogen phosphorylase B (PYGB) (Figures 1A and S1; Table S1). ABPP of serine hydrolases also revealed FASN upregulation, in addition to peptidases (dipeptidyl peptidase 9 [DPP9], acy/peptide hydrolase, and prolyl endopeptidase), lipases (PAFAH1B2 and PAFAH1B3), and sialic acid acetyltransferase (SIAE) (Figure 1B; Table S1). Metabolomic analysis yielded several metabolites that were commonly heighted across the four cell lines, including lipids (phosphatidyl ethanolamine [PE], phosphatidyl serine [PS], and sphingomyelin [SM]), the glycolytic intermediate phosphoenolpyruvate (PEP), nucleotides (AMP and uridine monophosphate [UMP], uridine-diphosphate-conjugated sugars (UDP-glucose and UDP-glucuronic acid), the sialic acid N-acetylneuraminic acid, the amino acid proline, and the antioxidant glutathione (Figure 1C; Table S1). Certain enzymes such as monacylglycerol lipase (MGLL), the serine protease fibroblast activation protein (FAP), and protein methyl esterase 1 (PPME1) were upregulated specifically by constitutive activation of TAZ (Figure S1; Table S1). Antioncogenic enzymes such as succinate.

Figure 1. Identifying Dysregulated Metabolic Enzymes in Breast Cancer Progression Model

(A) Shotgun proteomic profiling of metabolic enzyme expression in the breast cancer progression model by MudPIT. Upper heatmap shows relative protein expression of each protein, normalized to the highest expression of each protein across the five cell lines. Dark blue corresponds to high expression, and white or light blue corresponds to lower expression. Lower bar graphs show the metabolic enzymes that were significantly upregulated across 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells.

(B) ABPP of serine hydrolase activities in the breast cancer progression model by ABPP-MudPIT using the fluorophosphonate-biotin serine hydrolase activity-based probe. Upper heatmap shows relative serine hydrolase activities of each protein, normalized to the highest expression of each protein across the five cell lines. Dark blue corresponds to high activity, and white or light blue corresponds to lower activity. Lower bar graphs show the serine hydrolase activities that were significantly upregulated across 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells.

(C) Metabolomic profiling of the breast cancer progression model using SRM-based targeted liquid chromatography-tandem mass spectrometry. Upper heatmap shows relative metabolite activities normalized to MCF10A control cells. Dark blue corresponds to high levels, and white corresponds to lower levels. Lower bar graphs show the metabolites that were significantly elevated in levels across 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells. Data in bar graphs are presented as mean ± SEM; n = 4–6/group. Significance is presented as *p < 0.05 compared to MCF10A control cells, #p < 0.05 compared to MII cells. Detailed data are shown in Table S1. Characterization of breast cancer progression model, TAZ S89A-specific changes in metabolic enzymes, additional data showing regulation of these metabolic enzyme targets by the Hippo pathway, and additional data showing regulation of glycolytic metabolism by RAS and TAZ S89A are shown in Figure S1.
dehydrogenases (SDHAs) as well as several other citric acid cycle enzymes were specifically downregulated upon induction with TAZ S89A (Figure S1; Table S1).

Overall, our data indicate that cellular transformation and malignant progression heighten glycolysis and glycogen metabolism, de novo lipogenesis, nucleic acid metabolism, sialic acid metabolism, oxidative stress, and specific branches of lipid metabolism. Many of these pathways, including glycolytic and glycogen metabolism, nucleic acid metabolism, sialic acid metabolism, oxidative stress, and de novo lipogenesis, have been previously shown to be critical pathways that underlie cancer metabolism and pathogenicity. Nonetheless, we show that both HRAS transformation as well as constitutive activation of TAZ induces glycolytic, glycogen, and sialic acid metabolism and that TAZ and HRAS act synergistically in many cases (e.g., ENO1, GAPDH, PKM2, LDHA, ALDOA, PGK1, PYGB, UDP-glucose, and N-acetylenearaminic acid) to enhance these metabolic pathways (Figure S1). Additionally, we confirmed heightened glycolytic metabolism in these lines by measuring glucose consumption and lactic acid secretion and found that both are heightened upon transduction with TAZ S89A or HRAS and further heightened upon transduction with both TAZ S89A and HRAS. The highly malignant MIV cells also show significantly heightened glycolytic metabolism beyond that of MII cells (Figure S1). Interestingly, the enzymes specifically upregulated by TAZ, such as MGLL, FAP, and PPME1, or downregulated by TAZ, such as SDHA, have all been implicated as critical drivers of cancer progression (Bachovchin et al., 2011; Kelly, 2005; Nomura et al., 2011; Nomura et al., 2010b; Puustinen et al., 2009; Yang et al., 2013).

Our data indicate that many of the aforementioned metabolic enzymes are upregulated upon induction with TAZ S89A. We wanted to determine whether these enzymes are regulated by TAZ in aggressive MIV cells. Upon knocking down TAZ in MIV cells, we observed only modest reductions in the expression of the presumably TAZ-regulated targets, including PAFAH1B2, ENO1, ALDOA, DPP9, and NANS (Figure S1). Because both YAP and TAZ may regulate overlapping transcriptional targets, we proceeded to knockdown both YAP and TAZ in MIV cells. Interestingly, YAP and TAZ dual knockdown led to more robust reductions in the expression of most TAZ-regulated targets, including PAFAH1B2, ENO1, ALDOA, PGK1, LDHA, PKM2, DPP9, MGLL, and NANS (Figure S1). PAFAH1B3 was not altered, even upon TAZ and YAP knockdown (Figure S1). We interpret this lack of change to perhaps indicate that other oncogenic pathways, such as HRAS, may regulate this enzyme or that PAFAH1B3 may be regulated by postranslational mechanisms.

**Screening for Metabolic Enzymes that Are Required for Breast Cancer Pathogenicity**

We next sought to identify metabolic enzymes that, when inactivated, would impair cancer pathogenicity. We used small interfering RNA (siRNA) to transiently knockdown the expression of the dysregulated metabolic enzymes that we found through our profiling studies and identified those enzymes that impaired cellular proliferation, survival, or motility upon siRNA inactivation in MII TAZ S89A cells (Figures 2A–2D). To filter a large list of dysregulated metabolic enzyme targets, we narrowed our focus on those enzymes found by shotgun proteomics and ABPP and enzymes that control metabolites found by metabolomics that were altered across 10A TAZ S89A, MII, MII TAZ S89A, and MIV cells. Whereas inactivation of glycolytic-, glycogen-, and sialic-acid-metabolizing enzymes modestly impaired proliferative, survival, or migratory capacity, we were surprised to find that knockdown of PAFAH1B2 and PAFAH1B3 caused the most significant and dramatic impairments in the proliferative, survival, and migratory phenotypes in MII TAZ S89A cells (Figures 2A–2D). Thus, we decided to further investigate the role of PAFAH1B2 and PAFAH1B3 in breast cancer pathogenicity.

**Characterizing the Pathological Role of PAFAH1B2 and PAFAH1B3 in Breast Cancer**

Intrigued by our initial findings in our screen in the MII TAZ S89A cells, we next wanted to ascertain whether PAFAH1B2 and
PAFAH1B3 inactivation also impaired breast cancer pathogenicity in a more realistic patient-derived breast cancer cell line. We thus stably inactivated the expression of PAFAH1B2 and PAFAH1B3 in the highly aggressive estrogen receptor/progesterone receptor/HER2 receptor-negative (i.e., triple negative) human breast cancer cells, 231MFP, a line derived from a breast cancer patient adenocarcinoma MDA-MB-231 that has been in vivo passaged in mice to derive a malignant and more aggressive variant (Jessani et al., 2004). Using two independent short hairpin RNA oligonucleotides (shPAFAH1B2-1, shPAFAH1B2-2, shPAFAH1B3-1, and shPAFAH1B3-2), PAFAH1B2 and PAFAH1B3 were knocked down by >80% as measured by both quantitative PCR (qPCR) and ABPP-MudPIT (Figure 3A; Figure S2). Knockdown of PAFAH1B2 or PAFAH1B3 significantly impaired 231MFP cell proliferation, survival, migration, and invasiveness in culture and slowed or eliminated in vivo tumor growth in immune-deficient mice (Figures 3B–3F; Figure S2). Thus, our results suggest that PAFAH1B enzymes are important in maintaining aggressive features of cancer.

Upon profiling the gene expression of PAFAH1B2 and PAFAH1B3 in primary breast tumors, we found that PAFAH1B3, but not PAFAH1B2, was significantly heightened in human breast tumors compared to normal mammary tissue (Figure 3G). Based on the online Kaplan-Meier plotter resource for breast cancer recurrence-free survival, PAFAH1B3 expression is correlated with low recurrence-free survival in breast cancer patients overall, in lymph-node-positive tumors, and in grade 1–3 breast cancer patients (Figures 3H; Györffy et al., 2010).

From our phenotypic studies, we found that PAFAH1B3 inactivation produced more striking antitumorigenic effects compared with that of PAFAH1B2. Furthermore, PAFAH1B3 expression, but not PAFAH1B2 expression, was significantly higher in primary human breast tumors compared to normal tissue. Thus, we focused our attention on further investigating the pathophysiological and metabolic roles of PAFAH1B3 in driving breast cancer pathogenicity. Whereas we do not understand the mechanistic basis for the differences in tumor growth deficits conferred by PAFAH1B2 or PAFAH1B3 knockdown, it will be of future interest to analyze the tumors that grow out in shPAFAH1B2 xenograft tumors.

We next overexpressed both the catalytically active and the inactive serine to alanine mutant form of PAFAH1B3 (Ser47Ala or S47A) in MCF10A cells to determine whether this enzyme was sufficient to confer oncogenic properties (Figure S2). Whereas overexpression of the wild-type form of PAFAH1B3 did not alter proliferation or survival, wild-type PAFAH1B3, but not the catalytically inactive mutant, significantly enhanced cell migration, indicating that PAFAH1B3 exerts at least some of its pathogenic effects through its catalytic activity (Figure S2). Our studies also indicate that whereas PAFAH1B3 overexpression may be not sufficient to confer heightened proliferation or survival in the nontransformed MCF10A cells, its activity is sufficient to heighten mammary epithelial cell migration. Because PAFAH1B3 has been shown to interact with PAFAH1B2, PAFAH1B1, as well as ubiquitin ligase LNX1, it will be of future interest to coexpress these other binding partners to determine whether this coupled expression is sufficient to drive other malignant features of cancer (Rual et al., 2005; Sweeney et al., 2000).

Metabolomic Characterization of PAFAH1B3-Regulated Pathways in Breast Cancer

The putative function of PAFAH1B3 is to act as a deacetylase for the signaling lipid platelet-activating factor (PAF) (Hattori et al., 1995; Manya et al., 1999). Although recombinant PAFAH1B3 can cleave PAF in vitro (Figure S3), we found that extracellular and intracellular PAF levels are unchanged in shPAFAH1B2 and shPAFAH1B3 231MFP cells and PAFAH hydrolytic activity was not reduced upon PAFAH1B2 and PAFAH1B3 knockdown, indicating that PAFAH1B is not the dominant enzyme controlling PAF levels or PAF hydrolytic activity in 231MFP cells. Thus, PAFAH1B3 is likely not controlling cancer pathogenicity through controlling PAF-signaling pathways (Figure S3).

We next performed targeted and untargeted LC/MS-based metabolomic profiling to identify metabolic changes in the lipidsome conferred by PAFAH1B3 knockdown in 231MFP breast cancer cells (Figures 4A and 4B; Table S2). We subsequently interpreted only those changes in lipid levels that were significant between the two sh-oligonucleotides and in more than one experiment to reduce false positives or artifacts. We found that PAFAH1B3 knockdown raises the levels of several lipid species including phosphatidylcholines (PCs), lysophosphatidyl choline (LPC), PEs, lysophosphatidyl ethanolamines (LPEs), phosphatic acids (PAs), PSs, phosphatidyl glycerol (PGs), SMs, ceramide, sphingosine, triacylglycerols, and monoalkyl-glycerols, as well as other lipid counterparts (designated as “e” after lipid nomenclature; Figure 4C; Table S2). We screened the lipids that contain potential hydrolyzable bonds against purified PAFAH1B3, but none of these lipids were direct substrates of PAFAH1B3 and were not turned over (Figure S3). Thus, we interpret these changes to be indirect alterations in lipid metabolism stemming from PAFAH1B3 inactivation.

Interestingly, several of the lipids that were elevated upon PAFAH1B3 knockdown have been shown to possess antitumorigenic or proapoptotic effects. For example, ceramide levels are elevated upon PAFAH1B3 knockdown and ceramide is a well-established proapoptotic lipid (Morad and Cabot, 2013). The metabolites involved in ceramide biosynthesis, including phosphatidylcholine (PC) and sphingomyelin, also show heightened levels upon PAFAH1B3 knockdown. PS has been shown to be elevated in cancer cells undergoing apoptosis after chemotherapy or radiation treatment and is involved in immune recognition and tumor clearance (Chao et al., 2012). C16:0/C18:1 PC has been shown to act as a PPARα agonist, and PPARα agonists have been shown to have antitumorigenic and antiangiogenic properties (Chakravorthy et al., 2009; Huang et al., 2013; Liang et al., 2013; Pozzi and Capdevila, 2009). Consistent with this premise, we found that the PPARα agonist fenofibrate impaired cancer cell survival and proliferation in 231MFP cells and the PPARα antagonist GW6471 rescued the proliferative and survival defects of PAFAH1B3 knockdown (Figure S3). Interestingly, we also found that the elevated C16:0 LPC and C16:0/C18:1 PS also stimulated PPARα activity (Figure S3).

Whereas our metabolomic data still did not reveal the direct substrate of PAFAH1B3, our results indicate that PAFAH1B3 inactivation leads to a metabolomic signature that is enriched in tumor-suppressing signaling lipids that may be in part
**Figure 3. PAFAH1B2 and PAFAH1B3 Are Critical Metabolic Enzymes in Maintaining Breast Cancer Pathogenicity**

(A) We stably knocked down the expression of PAFAH1B2 and PAFAH1B3 in the triple-negative aggressive 231MFP breast cancer cells with two independent shRNA oligonucleotides by >80% as confirmed by qPCR.

(B–E) PAFAH1B2 and PAFAH1B3 knockdown impairs proliferation (B), serum-free cell survival (C), migration (D), and invasion (E).

(F) PAFAH1B2 and PAFAH1B3 knockdown also impairs tumor xenograft growth in immune-deficient SCID mice.

(G) Expression of PAFAH1B2 and PAFAH1B3 in normal mammary tissue and primary human breast tumors assessed by qPCR.

(H) Recurrence-free survival stratified by high versus low PAFAH1B3 expression in breast cancer patients overall and by lymph-node-negative/positive patients and grade 1–3 breast cancer patients. These data are derived from the online resource known as the Kaplan-Meier Plotter (http://www.kmplot.com; György et al., 2010). Data are presented as mean ± SEM; n = 4–8/group for (A–F), 7–41 patients/group for (G), and 306–3,455 patients for (H) as indicated. Significance is presented as *p < 0.05 compared to normal tissue in (A) and compared to shControl 231MFP cells for (B)–(G). p values for (H) are indicated on the figure itself. Protein expression data of PAFAH1B2 and PAFAH1B3 knockdown cells, a recapitulation of tumor growth deficits in shPAFAH1B3 cells, and PAFAH1B3 overexpression studies are shown in Figure S2.
The red and blue points correspond to elevated and reduced metabolites, respectively. The points to the left of the dotted line are ions detected, but not changing, in breast cancer cells. Data are presented as mean ± SEM; n = 5–6/group. Significance is presented as *p < 0.05 compared to shControl 231MFP breast cancer.

(D) Our results show that PAFAH1B3 inactivation leads to a metabolomic signature enriched in heightened levels of tumor-suppressing lipids such as ceramides and PPARγ ligands (e.g., PC, PS, and LPC). We postulate that this lipidomic signature contributes to reduced cancer pathogenicity upon PAFAH1B3 knockdown in breast cancer cells. Data are presented as mean ± SEM; n = 5–6/group. Significance is presented as *p < 0.05 compared to shControl 231MFP breast cancer cells. Detailed metabolomic data are shown in Table S2. PAF levels and PAF hydrolytic activity, lipid hydrolytic activities against PAFAH1B3, and studies testing the role of PPARs in PAFAH1B3 effects upon cancer are shown in Figure S3.

Conclusions

Here, we have used multiple platforms, including protein expression profiling, ABPP, and metabolomics, to broadly profile dysregulated metabolism in a breast cancer progression model that incorporates cellular transformation through HRAS and EMT, CSC-like features, and malignant progression through the constitutive activation of TAZ. In addition to identifying several canonical metabolic pathways, such as glycolysis, glycogen, and lipogenic metabolism, which have already been shown to be metabolic drivers of cancer, we have discovered PAFAH1B3 as an important metabolic enzyme that is important in driving responsible for the observed impairments in breast cancer pathogenicity and tumorigenicity.
aggressive and tumorigenic features of breast cancer. Metabolomic profiling reveals that PAFAH1B3 controls cancer cell pathogenicity through regulating an optimal landscape of signaling lipids that may impair cancer aggressiveness.

Whereas PAFAH1B3 has been implicated as a PAF acetylhydrolase, our data indicate that PAF is likely not the endogenous substrate of PAFAH1B3 in cancer cells. While we still do not know the identification of this endogenous substrate, the answer may lie in the altered metabolites that still remain unannotated from our metabolomic analyses of PAFAH1B3 inactivation. Identifying these unknown metabolites may further yield mechanisms through which PAFAH1B3 exerts its pathogenic effects in breast cancer cells. Alternatively, the endogenous substrate may also not be a lipid, or even a metabolite, and may operate on peptides, proteins, or protein posttranslational modifications. Thus, it would be of future interest to further investigate the direct substrates of PAFAH1B3 and how these substrates lead to the lipidomic changes that we observe in this study.

While we show that PAFAH1B2 and 1B3 knockdown lead to impairments in cellular proliferation, survival, migration, and invasiveness, the motility and invasiveness deficits may in part be due to the proliferative and survival deficits. Thus, it may be interesting to pursue those metabolic enzyme targets, such as SIAE or NANS, that do not show proliferative deficits but confer migratory impairments, because these targets may regulate invasiveness of the cancer cells. It will also be of future interest to investigate the roles of the other pathways and enzymes that are under the control of HRAS, TAZ, or HRAS and TAZ.

Overall, our results show many metabolic enzymes and biochemical pathways that are dysregulated during cellular transformation and also under malignant progression. Although we focused on PAFAH1B3 in this study due to the striking phenotypes observed, many of the other targets may represent unique metabolic nodes that influence various aspects of cancer pathogenicity. In this study, we have also identified multiple metabolic genes, activities, metabolites, and pathways that are regulated by the Hippo-signaling pathway. Previous studies have shown that the Hippo transducer pathway controls a diverse transcriptional network that drives EMT, cancer stem-like properties, proliferation, survival, motility, invasiveness, metastasis, and transformation (Cordenonsi et al., 2011; Lamar et al., 2012). Here, we show that the Hippo transducers YAP and TAZ collectively regulate the expression and activities of critical metabolic drivers of cancer pathogenicity. We show that the Hippo transducer pathway strongly regulates glycolytic enzymes and glycolytic metabolism alone or in conjunction with HRAS, thus likely contributing to the glycolytic addiction or the “Warburg effect” that subserves cancer pathogenicity. We also show here that the Hippo transducer pathway regulates many other metabolic enzymes that have been linked to controlling pathogenic features of cancer, including SDHA, FASN, MGLL, FAP, PPME1, and neutral cholesteryl ester hydrolase 1 (NCEH1, also known as KIAA1363). SDHA loss-of-function mutations, through accumulation of succinate and inhibition of alpha-ketoglutarate-dependent oxygenases, have been shown to enhance glycolysis, angiogenesis, and epigenetic alterations that fuel cancer (Yang et al., 2013). Both FASN and MGLL have been previously shown to be critical in cancer pathogenicity through controlling lipogenic and lipolytic pathways in cancer cells, respectively (Menzendeh and Lupu, 2007; Nomura et al., 2010b; 2011). FAP, a serine protease selectively expressed on tumor-associated fibroblasts and pericytes, has been shown to drive tumor stromagenesis and tumor growth (Santos et al., 2009). PPME1, a demethylase and inhibitor of protein phosphatase 2A, helps to promote protumorigenic phosphorylation signaling cascades (Bachovchin et al., 2011; Puustinen et al., 2009). Interestingly, NCEH1 is upregulated only upon induction of HRAS and TAZ S89A, indicating that both oncogenic stimuli are required for elevating KIAA1363 activity. This enzyme has been shown to drive cancer cell migration and tumorigenesis through controlling ether lipid-signaling pathways (Chang et al., 2011; Chiang et al., 2006). Thus, we show that the Hippo transducer is a critical factor in controlling the metabolic programming that drives the pathogenic properties of cancer.

Our studies underscore the utility of multidimensional metabolic profiling efforts in uncovering unique metabolic nodes in cancer, and we put forth PAFAH1B3 as a potential therapeutic target for the treatment of aggressive breast cancers.

**SIGNIFICANCE**

Whereas many recent studies have revealed key metabolic pathways that underlie cellular transformation, the metabolic drivers of cancer malignancy are less well understood. Here, we have performed a massively parallel metabolic profiling study to identify metabolic drivers underlying a breast cancer progression model that incorporates both cellular transformation by RAS and malignant progression by the Hippo transducer TAZ. We have discovered metabolic pathways including glycolytic, lipogenic, and lipolytic processes that have been previously linked to cancer pathogenicity that are coordinately regulated through both the RAS and Hippo pathways. Most notably, we have uncovered an important metabolic enzyme PAFAH1B3 as a critical driver of breast cancer pathogenicity through controlling tumor-suppressing signaling lipids. Overall, we show the utility of multidimensional metabolic profiling strategies in assembling a metabolic map of breast cancer progression and put forth PAFAH1B3 as a potential enzyme target for breast cancer therapy.

**EXPERIMENTAL PROCEDURES**

**Cell Lines**

The MCF10A, MII, MII TAZ S89A, and MIV lines were provided by Professor Stefano Piccolo at the University of Padua (Cordenonsi et al., 2011). The 231MFP cells were generated from explanted xenograft tumors of MDA-MB-231 cells, as described previously (Jessari et al., 2004).

**Cell Culture Conditions**

Human embryonic kidney 293T cells were cultured in Dulbecco’s modified Eagles’ medium (DMEM) media containing 10% fetal bovine serum (FBS) and maintained at 37°C with 5% CO₂. 231MFP cells were cultured in L15 media containing 10% FBS and glutamine and were maintained at 37°C in 0% CO₂. MCF10A and MCF10A-derived lines were cultured in DMEM/F12K media containing 5% (vol/vol) horse serum, 1% (vol/vol) penicillin-streptomycin-glutamine, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin,
Metabolomic Profiling of Cancer Cells

Activity-Based Protein Profiling of Cancer Cells

Shotgun Proteomic Profiling of Cancer Cells

Cancer Phenotype Studies

Metabolomic Profiling of Cancer Cells

RNA Interference of Enzymes

Overexpression of PAFAH1B2 or PAFAH1B3 in MCF10A Cells

Breast Tumor Array qPCR

Tumor Xenograft Studies

SUPPLEMENTAL INFORMATION

REFERENCES

ACKNOWLEDGMENTS

We thank the members of the D.K.N. research group and the K.L. laboratory for critical reading of the manuscript. This work was supported by grants from the NIH (R21CA170317, R01CA172667, and R00DA030908 to M.M.M., D.I.B., S.M.L., and D.K.N. and R01CA101891 to K.L.) and the Searle Scholar Foundation (to D.K.N.).

Received: February 11, 2014
Revised: May 12, 2014
Accepted: May 16, 2014
Published: June 19, 2014

Chemistry & Biology
PAFAH1B3 in Breast Cancer

10 ng/ml insulin, and 500 ng/ml hydrocortisone and maintained at 37°C at 5% (v/v) CO2 as described previously (Cordenonsi et al., 2011).

qPCR

qPCR was performed using the manufacturer’s protocol for Fischer Maxima SYBRGreen, with 10 μM primer concentrations. Primer sequences were derived from Primer Bank (Spanidios et al., 2010).

Cancer Phenotype Studies

Migration, invasion, cell proliferation, and survival studies were performed as described previously (Nomura et al., 2010b).

Shotgun Proteomic Profiling of Cancer Cells

Proteins (100 μg) were TCA precipitated in 20% TCA at –80°C overnight and then centrifuged at 10,000 x g at 4°C for 10 min to pellet protein. The protein pellets were washed three times with 8 M urea in PBS. After solubilization, 30 μl of 0.2% Protease Max Surfactant (Promega) was added and the resulting mixture was vortexed followed by the addition of 40 μl of 100 mM ammonium bicarbonate and 10 mM tris(2-carboxyethyl)phosphine. After 30 min, 12.5 mM iodoacetamide was added and allowed to react for 30 min in the dark before adding 120 μl PBS and 1.2 μl 1% Protease Max Surfactant (Promega). The protein solution was vortexed and 0.5 μg/μl Sequencing Grade Trypsin (Promega) was added and allowed to react overnight at 37°C. The peptide solution was subjected to a 30 min 10,000 x g spin before the supernatant was transferred to a new tube and loaded onto a biphasic (strong cation exchange/reverse phase) capillary column and analyzed by 2D liquid chromatography in combination with tandem mass spectrometry on a nanospray Thermo LTQ-XL MS/MS. The data were analyzed using the Integrated Proteomics Pipeline (IP2) as described previously (Nomura et al., 2010b).

Activity-Based Protein Profiling of Cancer Cells

ABPP-MudPIT analysis was performed using previously established procedures (Nomura et al., 2010b). Briefly, 1 mg protein was labeled with 5 μM fluorophosphonate-biotin in 1 ml PBS for 1 hr at room temperature, solubilized in 1% Triton X-100 for 1 hr, denatured, and labeled enzymes were enriched using avidin beads, reduced and alkylated, and tryspinized. Tryptic peptides were analyzed on a Thermo LTQ-XL MS/MS as described previously (Nomura et al., 2010b).

Metabolomic Profiling of Cancer Cells

Metabolite measurements were conducted using modified versions of previous procedures (Kopp et al., 2010; Nomura et al., 2010b). Details are described in Supplemental Experimental Procedures.

RNA Interference of Enzymes

For siRNA knockdown, cells were treated with ON-TARGETplus SMARTpool siRNA (Thermo) per the manufacturer’s protocol. Two hundred thousand cells were treated with 50 nM siRNA using DharmaFECT 1 Transfection Reagent. Assays were performed after 48 hr of treatment. We confirmed knockdown by qPCR.

We used short-hairpin RNA (shRNA) using two independent silencing oligonucleotides to knockdown the expression of PAFAH1B2 and PAFAH1B3 using previously described procedures (Nomura et al., 2010b). Details are described in Supplemental Experimental Procedures.

Overexpression of PAFAH1B2 or PAFAH1B3 in MCF10A Cells

Stable PAFAH1B3 overexpression was achieved by subcloning the PAFAH1B3 gene from fully sequenced human cDNA (Thermo Scientific) into the pLenti CMV puro DEST vector (Addgene 17452) using the gateway cloning system (Life Technologies). The PAFAH1B3 Ser 47 Ala mutant was made using Quick-Change Mutagenesis to mutate base 139 (Stratagene).

Breast Tumor Array qPCR

Breast cancer tumor array 1 was purchased from OriGene, and qPCR was performed on the array using the protocol described above.

Tumor Xenograft Studies

All experimental protocols used were approved by the Animal Care and Use Committee of the University of California, Berkeley. Human tumor xenografts were established by transplanting cancer cells ectopically into the flank of C.B17 severe combined immunodeficiency (SCID) mice (Taconic Farms) as described previously (Nomura et al., 2010b). Briefly, cells were washed two times with PBS, tryspinized, and harvested in serum-containing medium. Next, the harvested cells were washed two times with serum-free medium and resuspended at a concentration of 2.0 x 10^6 cells/μl and 100 μl was injected. Growth of the tumors was measured every 3–6 days with calipers.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.chembiol.2014.05.008.

AUTHOR CONTRIBUTIONS

M.M.M. designed research, performed research, analyzed data, and wrote the paper. D.I.B. performed research and analyzed data. A.S., M.G., T.N., and P.J.M. performed research. P.J.M. performed research, contributed new reagents, and analyzed data. K.L. designed research, analyzed data, contributed new reagents, and wrote the paper. D.K.N. designed research, performed research, analyzed data, and wrote the paper.

REFERENCES


Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination and migration, invasion, cell proliferation, and survival studies were performed as described previously (Nomura et al., 2010b). Briefly, cells were washed two times with PBS, tryspinized, and harvested in serum-containing medium. Next, the harvested cells were washed two times with serum-free medium and resuspended at a concentration of 2.0 x 10^6 cells/μl and 100 μl was injected. Growth of the tumors was measured every 3–6 days with calipers.


